[康霈*] Phase 3 clinical trial for CBL-514 injection to reduce abdominal subcutaneous fat approved in Canada.
康霈* announced that its second multi-center Phase 3 clinical trial (CBL-0302) for the new drug CBL-514, aimed at reducing abdominal subcutaneous fat, has been approved by Health Canada (HC). The trial will enroll 320 subjects across the US, Canada, and Australia.
📋 Article Processing Timeline
- 📰 Published: May 28, 2026 at 09:00
- 🔍 Collected: May 29, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 31, 2026 at 18:35 (58h 35m after Collected)
1. Date of event: 2026/05/28. 2. Drug name: CBL-514. 3. Purpose: Reduce subcutaneous fat, improve cellulite, treat Dercum's disease. 4. Development stages: Phase 1 completed, Phase 2 completed, Phase 3 ongoing. 5. Current status: The second pivotal Phase 3 trial (CBL-0302) received CTA approval from Health Canada on May 28, 2026. The study uses MRI and PR-AFRS as primary endpoints, targeting 320 subjects in the US, Canada, and Australia. 6. Next steps: Follow clinical trial progress. 7. Market status: High demand for non-invasive fat reduction, yet current products have limitations. 8. Risk warning: Drug development is long and costly; investors should exercise caution.
FAQ
What is a Phase 3 clinical trial?
The final stage of clinical testing to confirm the efficacy and safety of a drug before market approval.